Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated β-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6

Toxicology and Applied Pharmacology

Volumn 216, Issue 3, 2006, Pages 387-398

  Herraiz, Tomás ^a   Guillén, Hugo ^a   Arán, Vicente J ^b   Idle, Jeffrey R ^c   Gonzalez, Frank J ^d  

^a INSTITUTO DE FERMENTACIONES INDUSTRIALES CSIC   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c CHARLES UNIVERSITY   (Czech Republic)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

carbolines; 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 1 Methyl 4 phenylpyridinium; CYP2D6; Cytochrome P450; Hydroxylation; Isoquinolines; MAO; Metabolism; Monoamine oxidase; MPTP neurotoxin; N demethylation; Parkinson's disease; Polymorphism; Tetrahydro carbolines

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 HYDROXY N2 METHYL 1,2,3,4 TETRAHYDRO BETA CARBOLINE; BETA CARBOLINE; CARBOLINE DERIVATIVE; CYTOCHROME P450 2D6; ISOQUINOLINE ALKALOID; N2 METHYL 1,2,3,4 TETRAHYDRO BETA CARBOLINE; NEUROTOXIN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DEHYDROGENATION; DEMETHYLATION; DETOXIFICATION; DNA POLYMORPHISM; HYDROXYLATION; OXIDATION; STATISTICAL SIGNIFICANCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALKALOIDS; BIOTRANSFORMATION; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEALKYLATION; DOPAMINE AGENTS; HARMINE; HUMANS; HYDROXYLATION; INDICATORS AND REAGENTS; ISOQUINOLINES; KINETICS; MICROSOMES, LIVER; MONOAMINE OXIDASE; OXIDATION-REDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33750079907     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.06.003     Document Type: Article

References (87)

1. Adell A., Biggs T.A., and Myers R.D. Action of harman (1-methyl-beta-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 35 (1996) 1101-1107
2. Airaksinen M.M., and Kari I. β-carbolines, psychoactive compounds in the mammalian body: Part 2. Effects. Med. Biol. 59 (1981) 190-211
3. Albores R., Neafsey E.J., Drucker G., Fields J.Z., and Collins M.A. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 9368-9372
4. Baum S.S., Hill R., and Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleous accumbens of rats. Eur. J. Pharmacol. 314 (1996) 75-82
5. 13C-NMR. Bioorg. Medic. Chem. 13 (2005) 2975-2980
6. Bonnet R., Pavlovic S., Lehmann J., and Rommelspacher H. The strong inhibition of triosephosphate isomerase by the natural beta-carbolines may explain the neurotoxic actions. Neuroscience 127 (2004) 443-453
7. Cashman J.R., and Ziegler D.M. Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Mol. Pharmacol. 29 (1986) 163-167
8. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
9. Chiba K., Kubota E., Miyakawa T., Kato Y., and Ishizaki T. Characterization of hepatic microsomal metabolism as an in vivo detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Pharmacol. Exp. Ther. 246 (1988) 1108-1115
10. Chinta S.J., Pai H.V., Upadhya S.C., Boyd M.R., and Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Mol. Brain Res. 103 (2002) 49-61
11. Chinta S.J., Pai H.V., and Ravindranath V. Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver. Mol. Brain Res. 135 (2005) 81-92
12. Cobuzzi R.J., Neafsey E.J., and Collins M.A. Differential cytotoxycities of N-methyl-β-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J. Neurochem. 62 (1994) 1503-1510
13. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., and Tucker G.T. 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4. Implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277 (1996) 685-690
14. Collins M.A. Alkaloids, alcohol and Parkinson's disease. Parkinsonism Relat. Disord. 8 (2002) 417-422
15. Collins M.A., and Neafsey E.J. Beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): endogenous factors underlying parkinsonism?. Neurosci. Lett. 55 (1985) 179-184
16. Collins M.A., and Neafsey E.J. Potential neurotoxic "agents provocateurs" in Parkinson's disease. Neurotoxicol. Teratol. 24 (2002) 571-577
17. Deng Y., Newman B., Dunne M.P., Silburn P.A., and Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol. 55 (2004) 897
18. Ding S., Yao D., Deeni Y.Y., Burchell B., Wolf C.R., and Friedberg T. Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathways. Biochem. J. 356 (2001) 613-619
19. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., Alperovitch A., Chartier-Harlin M.C., and Tozourio C. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 55 (2004) 430-443
20. Evans W.E., and Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 429 (2004) 464-468
21. Fekkes D., and Bode W.T. Occurrence and partition of the β-carboline norharman in rat organs. Life Sci. 52 (1993) 2045-2054
22. Fonne-Pfister R., Bargetzi M.J., and Meyer U.A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine-4-hydroxylation. Biochem. Biophys. Res. Commun. 148 (1987) 1144-1150
23. Fukuda T., Nishida Y., Imaoka S., Hiroi T., Naohara M., Funae Y., and Azuma J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380 (2000) 303-308
24. Gearhart D.A., Collins M.A., Lee J.M., and Neafsey E.J. Increased beta-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol. Dis. 7 (2000) 201-211
25. Gilham D.E., Cairns W., Paine M.J.I., Modi S., Poulsom R., Roberts G.C.K., and Wolf C.R. Metabolism of MPTP by cytochrome P450 2D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27 (1997) 111-125
26. Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P., and Meyer U.A. Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism. Nature 331 (1988) 442-446
27. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz de Montellano R. (Ed). Cytochrome P450: Structure, Mechanism, and Biochemistry (2005), Kluwer, New York 377-530
28. Hanna I.H., Krauser J.A., Cai H., Kim M.-S., and Guengerich F.P. Diversity in mechanisms of substrate oxidation by Cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J. Biol. Chem. 276 (2001) 39553-39561
29. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
30. Herraiz T. Analysis of the bioactive alkaloids tetrahydro-β-carboline and β-carboline in food. J. Chromatogr. A 881 (2000) 483-499
31. Herraiz T. Tetrahydro-β-carboline bioactive alkaloids in beverages and foods. ACS Sympos. Ser. 871 (2004) 405-426
32. Herraiz T. Relative exposure to β-carbolines norharman and harman from foods and tobacco smoke. Food Addit. Contamin. 21 (2004) 1041-1050
33. Herraiz T., and Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 326 (2005) 378-386
34. Herraiz T., and Chaparro C. Human monoamine oxidase enzyme inhibition by coffee and β-carbolines norharman and harman isolated from coffee. Life Sci. 78 (2006) 795-802
35. Herraiz T., and Galisteo J. Tetrahydro-β-carboline alkaloids that occur in foods and biological systems act as radical scavengers and antioxidants in the ABTS assay. Free Radical Res. 36 (2002) 923-928
36. Herraiz T., and Galisteo J. Endogenous and dietary indoles: a class of antioxidants and radical scavengers in the ABTS assay. Free Radical Res. 38 (2004) 323-331
37. Husbands S.M., Glennon R.A., Gorgerat S., Gough R., Tyacke R., Crosby J., Nutt D.J., Lewis J.W., and Hudson A.L. β-Carboline binding to imidazoline receptors. Drug Alcohol Depend. 64 (2001) 203-208
38. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 207 (2005) S52-S56
39. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics J. 5 (2005) 6-13
40. Jiménez-Jiménez F.J., Tabernero C., Mena M.A., de Yébenes J.G., de Yebenes M.J.G., Casarejos M.J., Pardo B., Garcia Agundez J.A., Benitez J., Matinez A., and García-Asenjo J.A.L. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated as a poor metaboliser of debrisoquine. J. Neurochem. 57 (1991) 81-87
41. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., and Ingelman-Sundberg M. Inherited amplification of an active gen in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11825-11829
42. Johansson I., Oscarson M., Yue Q.Y., Bertilsson L., Sjoqvist F., and Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46 (1994) 452-459
43. Kalgutkar A.S., Zhou S., Fahmi O.A., and Taylor T.J. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6. Drug Metab. Dis. 31 (2003) 596-605
44. Langston J.W., Ballard P., Tertrud J.W., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
45. +: identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48 (1984) 87-92
46. Lorenc-Koci E., Wójcikowski J., Kot M., Haduch A., Boksa J., and Daniel W.A. Disposition of 1,2,3,4-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Res. 996 (2004) 168-179
47. Louis E.D., Zheng W., Jurewicz E.C., Watner D., Chen J., Factor-Litvak P., and Parides M. Elevation of blood β-carboline alkaloids in essential tremor. Neurology 59 (2002) 1940-1944
48. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., and Smith R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet 2 (1977) 584-586
49. + in actively dividing and differentiated PC12 cells. Gene Expression 11 (2003) 117-124
50. Matsubara K., Collins M.A., Akane A., Ikebuchi J., Neafsey E.J., Kagawa M., and Shiono H. Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res. 610 (1993) 90-96
51. + analogs, in the lumbar cerebrospinal fluid of parkinsonian patients. Nerurology 45 (1995) 2240-2245
52. McCann S.J., Pond S.M., James K.M., and Le Couteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci. 153 (1997) 50-53
53. McElvain S.M., and Berger R.S. Piperidine derivatives: XXVII. The condensation of 4-piperidones and piperidinols with phenols. J. Am. Chem. Soc. 77 (1955) 2848-2850
54. Miksys S., and Tyndale R.F. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev. 36 (2004) 313-333
55. Miksys S., Rao Y., Hoffmann E., Mash D.C., and Tyndale R.F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 82 (2002) 1376-1387
56. Modi S., Gilham D.E., Sutcliffe M.J., Lian L.Y., Primrose W.U., Wolf C.R., and Roberts G.C.K. 1-Methyl-4-phenyl-1,2,3,4-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36 (1997) 4461-4470
57. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res. 29 (1997) 99-111
58. Nagatsu T. Amine-related neurotoxins in Parkinson's disease. Past, present and future. Neurotoxicol. Teratol. 24 (2002) 565-569
59. Naoi M., Maruyama W., Niwa T., and Nagatsu T. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J. Neural Transm. (supplement) 41 (1994) 197-205
60. Narimatsu S., Tachibana M., Masubuchi Y., and Suzuki T. Cytochrome P4502D and -2C enzymes catalyze the oxidative N-demethylation of the Parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyiridine in rat liver microsomes. Chem. Res. Toxicol. 9 (1996) 93-98
61. O'Carrol A.M., Anderson M.C., Tobbia I., Phillips J.P., and Tipton K.F. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues. Biochem. Pharmacol. 38 (1989) 901-905
62. Pai H.V., Kommaddi R.P., Chinta S.J., Mori T., Boyd M.R., and Ravindranath V. A frameshift mutation and alternate splicing in human brain generate a functional form of pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem. 279 (2004) 27383-27389
63. Paine M.J.I., Scrutton N.S., Munro A.W., Gutierrez A., Roberts G.C.K., and Wolf C.R. Electron transfer partners of cytochrome P450. In: Ortiz de Montellano R. (Ed). Cytochrome P450: Structure, Mechanism, and Biochemistry (2005), Kluwer, New York 115-148
64. Parker C.A., Anderson N.J., Robinson E.S., Price R., Tyacke R.J., Husbands S.M., Dillon M.P., Eglen R.M., Hudson A.L., Nutt D.J., Crump M.P., and Crosby J. Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 43 (2004) 16385-16392
65. Perry T.L., Jones K., Hansen S., and Wall R.A. 4-Phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Neurosci. Lett. 75 (1987) 65-70
66. Persad A.S., Stedeford T., Tanaka S., Chen L.P., and Banasik M. Parkinson's disease and CYP2D6 polymorphism in Asian populations: a meta analysis. Neuroepidemiology 22 (2003) 357-361
67. Ramamoorthy Y., Tyndale R.F., and Sellers E.M. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11 (2001) 477-487
68. Ravindranath V. Metabolism of xenobiotics in the central nervous system. Biochem. Pharmacol. 56 (1998) 547-551
69. Riedl A.G., Watts P.M., Jenner P., and Marsden C.D. P450 enzymes and Parkinson's disease: the story so far. Mov. Disord. 13 (1998) 212-220
70. Robinson E.S.J., Anderson N.J., Crosby J., Nutt D.J., and Hudson A.L. Endogenous β-carbolines as clonidine-displacing substances. Ann. N. Y. Acad. Sci. 1009 (2003) 157-166
71. Ruiz-Durantez E., Ruiz-Ortega J.A., Pineda J., and Ugedo L. Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett. 308 (2001) 197-200
72. 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J. Neurosci. 12 (1992) 1977-1999
73. Siegle I., Fritz P., Eckhardt K., Zanger U.M., and Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11 (2001) 237-245
74. Smith C.A., Gough A.C., Leigh P.N., Summers B.A., Harding A.E., Maraganore D.M., Sturman S.G., Schapira A.H., Williams A.C., Spurr N.K., and Wolf C.R. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339 (1992) 1375-1377
75. Storch A., Hwang Y.I., Gearhart D.A., Beach J.W., Neafsey E.J., Collins M.A., and Schwarz J. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. J. Neurochem. 89 (2004) 685-694
76. Suzuki T., Fujita S., Narimatsu S., Masubuchi Y., Tachibana M., Ohta S., and Hirobe M. Cytochrome P450 isozymes catalysing the 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J. 6 (1992) 771-776
77. Tan A.K., and Ramsay R.R. Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. Biochemistry 32 (1993) 2137-2143
78. Thum T., and Borlak J. Gen expression in distinct regions of the heart. Lancet 355 (2000) 979-983
79. Tyndale R.F., Li Y., Li N.-Y., Messina E., Miksys S., and Sellers E.M. Characterization of cytochrome P-450 2D1 activiy in rat brain: high-affinity kinetics for dextrome thorpan. Drug. Metab. Dispos. 27 (1999) 924-930
80. Upadhya S.C., Boyd M.R., and Ravindranath V. Characterization and localization of cytochrome P450 mediated metabolism of MPTP to nor-MPTP in mouse brain: relevance to Parkinson's disease. Neurotoxycity Res. 3 (2001) 369-380
81. Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., and Corsini G.U. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine-induced mouse model of Parkinson's disease. J. Neurochem. 91 (2004) 285-298
82. Weissman J., Trevor A., Chiba K., Peterson L.A., Caldera P., Castagnoli N., and Baillie T. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28 (1985) 997-1001
83. Youdim M.B.H., Edmondson D., and Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev., Neurosci. 7 (2006) 295-309
84. Yu A., Kneller B.M., Rettie A.E., and Haining R.L. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 303 (2002) 1291-1300
85. Yu A.M., Idle J.R., Byrd L.G., Krausz K.W., Küpfer A., and Gonzalez F.J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13 (2003) 173-181
86. Yu A.M., Idle J.R., Herraiz T., Küpfer A., and Gonzalez F.J. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13 (2003) 307-319
87. Zanger U.M., Fischer J., Raimundo S., Stuven T., Evert B.O., Schwab M., and Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 (2001) 573-585